AstraZeneca is scheduled to report results for the third quarter ... Deutsche Bank analysts said a recent late-stage trial of the experimental drug, which didn't significantly improve overall survival ...
GlobalData on MSN2d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trialThe companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...
AstraZeneca is gearing up for a mid-stage trial of AZD6234 in combination with its weekly GLP-1/glucagon candidate AZD9550. This once-weekly combo treatment should provide a “triple mechanism ...
Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...
AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...
AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004 ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial. The Phase I trial, which had 72 participants ...
LONDON, United Kingdom - AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback